Piper Sandler Keeps Their Buy Rating on Natera (NTRA)
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Natera, with a price target of $230.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Westenberg is a 4-star analyst with an average return of 9.9% and a 48.71% success rate. Westenberg covers the Healthcare sector, focusing on stocks such as Natera, Adaptive Biotechnologies, and Guardant Health.
In addition to Piper Sandler, Natera also received a Buy from Citi’s Patrick B Donnelly in a report issued today. However, on the same day, Wells Fargo maintained a Hold rating on Natera (NASDAQ: NTRA).
Based on Natera’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $592.18 million and a GAAP net loss of $87.54 million. In comparison, last year the company earned a revenue of $439.76 million and had a GAAP net loss of $31.59 million
Based on the recent corporate insider activity of 197 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTRA in relation to earlier this year. Most recently, in December 2025, Herm Rosenman, a Director at NTRA sold 48,419.00 shares for a total of $11,011,230.68.
Read More on NTRA:
Disclaimer & DisclosureReport an Issue
- Natera price target raised to $257 from $239 at Baird
- Natera price target raised to $280 from $270 at Barclays
- Natera: Underpenetrated Growth, Emerging Catalysts, and a Clear Path to Cash Flow Support a Buy Rating
- Natera reports FY25 EPS ($1.52), consensus ($2.42)
- Natera says Phase 2 SINERGY trial met primary endpoint
